Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2010. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
On July 13, 2010, the Administrators of the SmithKline Beecham Mid-Term Incentive Plan notified the Company of an increase in interests in Ordinary share ADRs for specific individuals. This increase resulted from the re-investment of dividends paid to shareholders on July 8, 2010.
- Transaction Price: $34.91 per ADR
- Mr E J Gray: 17.15 ADRs
- Mr D J Phelan: 519.93 ADRs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of ADRs held by Mr E J Gray and Mr D J Phelan post-transaction.
- Confirm the dividend payment date of July 8, 2010, and the reinvestment mechanism details.
- Check the market price of GSK ADRs on July 13, 2010, to contextualize the $34.91 transaction price.